The anticancer effect of genetic inhibition of GNA14 was valid in the context of constitutive activation of MAPK and β-catenin signaling, demonstrating the potential value of GNA14 as a therapeutic target for the treatment of colorectal cancer in the presence of KRAS mutations and APC truncating mutations. The gene discussed is KRAS; the disease is colorectal cancer.